FDA has approved vepdegestrant (VEPPANU), the first PROTAC therapy, for adults with ESR1-mutated ER+/HER2- advanced or ...
Sonire’s first U.S. study of ultrasound-guided, anesthesia-free HIFU ablation therapy has been launched for patients with ...
A new American Academy of Dermatology survey finds that social media misinformation has driven more than 16 million U.S.
A new Cell study suggests that T cell exhaustion in tumors is driven in part by failed proteostasis, causing damaged and ...
AidaBREAST® received FDA Breakthrough Device designation as a multi-omic assay for women with stage I–IIa invasive breast ...
Phase 2 OPTIMAL-PSMA dosimetry data suggest that TLX597-Tx, a next-generation PSMA-targeting radioligand therapy, demonstrated low salivary gland and kidney uptake in metastatic castration-resistant ...
The Phase 3 MagnetisMM-5 trial showed that elranatamab (ELREXFIO) significantly improved progression-free survival versus ...
The Phase 2 LARA trial reported encouraging activity for pembrolizumab plus lenvatinib in recurrent gynaecological clear cell ...
The world’s first Nectin-4-targeting ADC to enter Phase III development in triple-negative breast cancer is now being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results